PharmD Fellowship 2020-2022

Flexion Therapeutics

Flexion Therapeutics is a biopharmaceuticalcompany focused on the development and

commercialization of novel, local therapies forthe treatment of patients with musculoskeletalconditions, beginning with osteoarthritis (OA),

a type of degenerative arthritis.

We embrace a philosophy of scientificentrepreneurship which spurs innovation and

empowers and inspires our people to helpmake a meaningful difference in the lives of

patients.

Who We Are

With a foundation of respect, integrityand excellence, we have strong core

values - focus, ingenuity, tenacity,transparency and fun - that serve as

our internal compass.

Our Core ValuesOur Guiding PrinciplesScientific Entrepreneurship: Embrace ingenuity and new

models for advancing scientific innovation.Transformative Medicine: Identify and advance breakthrough

science to effectively treat musculoskeletal diseases.Improving Lives: Address unmet needs and make a

meaningful difference in the lives of people confrontingmusculoskeletal diseases by providing innovative therapies.

Our PipelineTriamcinolone acetonide extended-release, Flexion’s first approved product (known as Zilretta®), leveragesFlexion’s proprietary microsphere technology in a formulation that uses a poly lactic-co-glycolic acid (PLGA)matrix to extend the release of triamcinolone acetonide, a commonly administered, short-acting corticosteroid.Zilretta was approved by the U.S. Food and Drug Administration on October 6, 2017. Flexion continues to investigate triamcinolone acetonide extended-release and the potential utilization of ourproprietary microsphere technology in other novel formulations to help patients with musculoskeletal conditions. FX201 is a locally administered gene therapy designed to stimulate the production of an anti-inflammatoryprotein, interleukin-1 receptor antagonist (IL-1Ra), whenever inflammation is present within the joint. Bypersistently suppressing inflammation, FX201 may both reduce pain and modify the disease. Based on strongpreclinical data, a single injection of FX201 could potentially enable expression of IL-1Ra in an osteoarthriticjoint for at least a year. Flexion intends to initiate a Phase 1 clinical trial in 2019. FX301 is a preclinical program consisting of a NaV1.7 inhibitor formulated for extended-release from athermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheralnerve block for control of post-operative pain. Flexion believes FX301 has the potential to provide effective painrelief while preserving motor function. The company anticipates initiating FX301 clinical trials in 2021.

The Fellowship

The Flexion Medical Affairs team is dedicated to identifying, generating, communicating andgathering scientific knowledge of musculoskeletal conditions as trusted scientific colleagues andstrategic business partners, ultimately improving the management of patients with theseconditions.

Create Medical Information Standard Response LettersContribute to Medical Communications strategyAuthor medical publicationsAttend Medical Congress to gather medical insights orstaff medical boothContribute to Medical Content, Grant, and Investigator-Initiated Research Review CommitteesCoordinate Advisory BoardsComplete Medical Science Liaison (MSL) scientifictraining curriculum and attend field rides with a FlexionMSL

Core:Medical Information and TrainingMedical CommunicationsMedical OperationsHealth Economic and OutcomesResearch and Real-World Evidence

Elective:

Field Medical AffairsPharmacovigilanceOthers based on Fellow’s interest

Areas of Focus Potential Activities

Concentration: Medical AffairsDuration: 2 yearsLocation: Burlington, MA

About Medical Affairs

Through the Flexion Fellowship Program, the Fellow will gain the necessary skills for asuccessful career in the pharmaceutical industry, as well as valuable academic skills whilepartnering with Northeastern University faculty. The Medical Affairs Fellow will be a key memberof the Medical Affairs team, with the ability to contribute to multiple projects across the MedicalAffairs function during the 2-year Fellowship.

Our Fellowship